236 related articles for article (PubMed ID: 32306127)
1. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach.
Ma F; Wang B; Xue L; Kang W; Li Y; Li W; Liu H; Ma S; Tian Y
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2135-2142. PubMed ID: 32306127
[TBL] [Abstract][Full Text] [Related]
2. Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study.
van der Veen A; Seesing MFJ; Wijnhoven BPL; de Steur WO; van Berge Henegouwen MI; Rosman C; van Sandick JW; Mook S; Haj Mohammad N; Ruurda JP; Brosens LAA; van Hillegersberg R;
Eur J Surg Oncol; 2018 Dec; 44(12):1955-1962. PubMed ID: 30201419
[TBL] [Abstract][Full Text] [Related]
3. [A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
Nakai M; Kawasaki H; Wajima N; Kimura A; Nakayama Y; Muroya T; Yonaiyama S; Okano K; Nagase H; Hakamada K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2301-3. PubMed ID: 24394092
[TBL] [Abstract][Full Text] [Related]
4. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Neoadjuvant Chemotherapy for Advanced Gastric Cancer in Elderly Patients.
Mukoyama T; Kanaji S; Sawada R; Harada H; Urakawa N; Goto H; Hasegawa H; Yamashita K; Matsuda T; Oshikiri T; Kakeji Y
Anticancer Res; 2023 Dec; 43(12):5649-5656. PubMed ID: 38030165
[TBL] [Abstract][Full Text] [Related]
6. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
[TBL] [Abstract][Full Text] [Related]
7. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
8. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients.
Xie JW; Lu J; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Li P; Huang CM
BMC Cancer; 2018 Oct; 18(1):1021. PubMed ID: 30348122
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
10. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
Chen J; Wang A; Ji K; Bu Z; Ji J
BMC Cancer; 2020 Aug; 20(1):777. PubMed ID: 32811471
[TBL] [Abstract][Full Text] [Related]
11. [A case of mixed adenoneuroendocrine carcinoma of the stomach].
Muto M; Muto M; Ichiki K; Ishikawa C; Inoue M; Ishii D; Goto J; Inaba S; Aoki T; Kondo N
Nihon Shokakibyo Gakkai Zasshi; 2016; 113(10):1769-1776. PubMed ID: 27725466
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Locally Advanced Neuroendocrine Carcinoma of the Stomach Could be Curably Resected after Chemotherapy with CPT-11/CDDP].
Kido T; Morimoto Y; Toda H; Yoshino K; Imano H; Sasaki T; Kimura Y; Saito R; Endo K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1532-1534. PubMed ID: 29394692
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
Lin JP; Zhao YJ; He QL; Hao HK; Tian YT; Zou BB; Jiang LX; Lin W; Zhou YB; Li Z; Xu YC; Zhao G; Xue FQ; Li SL; Fu WH; Li YX; Zhou XJ; Li Y; Zhu ZG; Chen JP; Xu ZK; Cai LH; Li E; Li HL; Xie JW; Huang CM; Li P; Lin JX; Zheng CH
Br J Surg; 2020 Aug; 107(9):1163-1170. PubMed ID: 32323879
[TBL] [Abstract][Full Text] [Related]
14. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
18. [Conversion Therapy Using Etoposide and Cisplatin Chemotherapy for Liver Metastases from Advanced Gastric Mixed Adenoneuroendocrine Carcinoma - A Case Report].
Inaba Y; Fujita M; Ninomiya R; Hashimoto D
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1488-1490. PubMed ID: 29394677
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.
Lin Z; Chen J; Guo Y
Medicine (Baltimore); 2019 Jun; 98(23):e16000. PubMed ID: 31169743
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.
Lim SM; Kim H; Kang B; Kim HS; Rha SY; Noh SH; Hyung WJ; Cheong JH; Kim HI; Chung HC; Yun M; Cho A; Jung M
Ann Nucl Med; 2016 May; 30(4):279-86. PubMed ID: 26837515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
